Presentation at ISAM May 2021, Boise Idaho

SolAeroMed CEO presented clinical study results in Bronchiectasis at the International Socieity of Aerosol Medicine meeting in Boise Idaho in May 2021.  Ensuing discussion led to 3rd party interest from US clinicians to engage in future clinical trials of S1226.

Read more

$1.5 million investment round announced to progress COVID -19 clinical trial

We have constructed a term sheet to raise $1.5 million to support a Phase II clinical trial in COVID patients in local Alberta hospitals.  We maintain the current $7.50 share price and $20M company valuation.  Proceeds will be used over the next few months to: Support the purchase of drug components (500 treatment doses) Progress

Read more

Health Canada signs regulatory approval for S-1226 COVID Phase II clinical trial

On the eve of 2021 SolAeroMed received regulatory notification from Health Canada that our proposed clinical trial of S-1226 in COVID patients received official approval. This is approval was a long time coming and SolAeroMed management had been in discussions with Health Canada for 6 months working to address issues around the design of the

Read more

SolAeroMed advances discussion with European partners on development of S-1229 as platform drug technology based on granting of European cyclodextrin patent.

While most of SolAeroMed efforts are focused on advancing clinical trial development of our lead CO2/perflubron S-1226 drug, we have also made recent progress in our S-1229 Cyclodextrin drug technology.   Our pre-clinical and in vitro R&D demonstrates that inhaled cyclodextrin can remove excess cholesterol and repair dysfunctional lung surfactant.  Dysfunctional surfactant is a feature of

Read more

Treatment of Acute Asthma in the ICU

In October 2017 we were able to treat a severely ill asthmatic patient in Calgary ICU with our experimental S1226 drug. Results were in the words of the lead clinician ‘shockingly good’. This case study was presented in May at the American Thoracic Society meeting in San Diego. Full presentation available in poster form.

Read more

SolAeroMed Investment Announcement

CALGARY, AB – December 6, 2016. SolAeroMed Inc. is excited to report a brand new investment opportunity. Please click here to find out more information about our new investment announcement for shares with a warrant.

Read more

1 2 3
top